Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data ...

You've put countless hours — and likely thousands of dollars — into making sure your wedding is everything you've dreamed about. But all that effort can't guarantee something won't go wrong ...